Navigation Links
Visceral Leishmaniasis: Successful Vaccine Trial In Dogs

g-term protection against visceral leishmaniasis.

Although this vaccine’s effectiveness has been shown only on a limited number of animals, it is a further step towards protection of dogs against this disease. These results, confirmed indeed by the first, highly encouraging, data from a large-scale clinical trial currently under way (phase III), are promising for efforts to reduce transmission of leishmaniasis to humans. They also point to new lines of investigation for elaborating a possible human vaccine. An integrated research project, involving several IRD groups (2), has just been set up in India, to work on this. It should lead to an assessment of the effectiveness of such a vaccine in humans.

(1) The finding of these proteins furthermore necessitated the development, achieved in 1992, of suitable culture media (patented), with the attached proteins removed. The media normally used ijn fact contain many protein-containing compounds (serumalbumins, albumins etc.) which prevent specific isolation of the proteins excreted by the parasite. References : Lemesre J.L., Blanc M.P., Grébaut P., Zilberfard V. et Carrière V. (1994). Culture continue de formes amastigotes de Leishmanies en condition axénique. Réalisation du cycle évolutif in vitro. Médecine et Armées, 22 (1), 99 and Merlen T, Sereno D, Brajon N. and Lemesre J.L. (1999). Leishmania Spp: completely defined medium without serum and macromolecules (CDM/LP) for the continuous in vitro cultivation of infective promastigote forms. Am. J. Trop. Med. Hyg., 60 (1), 41-50. Brevets : Lemesre J.L. (1993). "Procédé de culture in vitro de différents stades parasitaires obtenus et applications biologiques". Brevet français, FR n° 93 05779 ; Lemesre J.L. (1994)."Method for the culture in vitro of different stages of tissue parasites".Brevet international, PCT/FR N° 94/00577.

(2) The project, entitled « Study of the host and parasite factors determining the outcome of visceral leishmaniasis: applica
'"/>

Source:Institut de Recherche Pour le D茅veloppement


Page: 1 2 3 4

Related biology news :

1. Successful Test Of Single Molecule Switch Opens The Door To Biomolecular Electronics
2. Penn Surgeons Use Completely Robotic Surgery to Successfully Treat Prostate Cancer
3. Successful cell engineering may lead to mad cow prevention, say researchers
4. Successful transplantation from pig embryos to mice
5. Successful lung cancer surgery not enough to break nicotine dependence in many smokers
6. FDA Approves Human Hookworm Vaccine for Phase I Safety Trials
7. Live Recombinant Adenovirus Vaccine Technique Explored
8. Gene Vaccine Protects Mice Against Development Of Her2/neu Breast Cancer
9. NIAID Initiates Trial of Experimental Avian Flu Vaccine
10. Study Models Impact Of Anthrax Vaccine
11. New Insights Into HIV Immunity Suggest Alternative Approach to Vaccines
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Visceral Leishmaniasis Successful Vaccine Trial Dogs

(Date:3/31/2015)... 31, 2015   Guidepoint , a leading global ... Post-Surgical Pain Management TRACKER, part of the Guidepoint ... in the medical device and therapeutics markets. The Post-Surgical ... treatment volumes, market share, and adoption rates across three ... joint surgery. The Post-Surgical Pain Management TRACKER ...
(Date:3/24/2015)... --  NexID Biometrics LLC, whose spoof-mitigation technology boosts ... the beginning of shipments of version 2.0 of its ... based in Potsdam, N.Y. , is ... began here today at the Walter E. Washington Convention ... SDK boosts the accuracy rate range to 96.5 to ...
(Date:3/23/2015)... Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), a ... announces its biometric payment technology, the Wocket® smart wallet, will ... 30 th . The new 30 ... markets. Gino Pereira , ... ad campaign following the recent initial shipment of Wocket smart ...
Breaking Biology News(10 mins):Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3
... Researchers at Loyola University Chicago Stritch School of ... the National Institutes of Health to study vitamin D ... evaluate the relation between low vitamin D levels and ... disease. Evidence from numerous previous studies is "inconclusive ...
... N.C. Researchers at the University of North Carolina at ... and paste together different viruses in an effort to create ... clinical trial, the investigators found no side effects from using ... muscle protein in patients with muscular dystrophy. "This trial ...
... Bethesda, MDUsing magnetic resonance imaging (MRI) and nanoparticle technology, ... the growth of laboratory-engineered blood vessels after they have ... step toward ensuring that blood vessels, and possibly other ... taking hold and working as expected. Until now, there ...
Cached Biology News:Loyola receives NIH grant to study vitamin D deficiency in African populations 2Clinical trial for muscular dystrophy demonstrates safety of customized gene therapy 2Yale researchers develop a way to monitor engineered blood vessels as they grow in patients 2
(Date:4/1/2015)...  Spherix Incorporated (Nasdaq: SPEX ) -- an intellectual ... monetization of intellectual property, today announced that Chardan ... global investment bank specializing in micro, small, and ... Spherix. The report, authored by ... Chardan, was published on March 31, 2015. The ...
(Date:4/1/2015)... (PRWEB) April 01, 2015 Earlier this ... a vibrant life sciences industry association that represents research-based ... members. , Jonathan Parker, AJO’s Vice President of ... Dinner in February, an event that attracted over 750 ... Don Wright, a 73 year old cancer survivor shared ...
(Date:3/31/2015)... 31, 2015 CytoSorbents Corporation (NASDAQ CM: ... purification to treat critically-ill and cardiac surgery patients ... and reports financial results for the fiscal year ... CytoSorb® product revenues were a record $3.1M, an ... CytoSorb® revenues of $0.8M Highlights for the Year ...
(Date:3/31/2015)... Eastern Kentucky University is ranked ... of criminal justice degree programs by Nonprofitcollegesonline.com. , ... ideas and high quality educational opportunities,” Editor Liz ... We are confident that students will find both ... the site’s first “Students before Profits” list, and ...
Breaking Biology Technology:Chardan Capital Issues Industry Note Covering Spherix 2Chardan Capital Issues Industry Note Covering Spherix 3HR Consulting Firm, A.J. O'Connor Associates Joins BioNJ – The Vibrant 400 Member Strong Life Sciences Industry Association - and Attends its Annual Dinner 2CytoSorbents Reports Record 2014 Revenue 2CytoSorbents Reports Record 2014 Revenue 3CytoSorbents Reports Record 2014 Revenue 4CytoSorbents Reports Record 2014 Revenue 5CytoSorbents Reports Record 2014 Revenue 6CytoSorbents Reports Record 2014 Revenue 7CytoSorbents Reports Record 2014 Revenue 8CytoSorbents Reports Record 2014 Revenue 9CytoSorbents Reports Record 2014 Revenue 10CytoSorbents Reports Record 2014 Revenue 11EKU Ranked in Top 50 Among Online Criminal Justice Degrees 2
... Pharmaceuticals is,pleased to announce the introduction of ... on medically based aesthetics and,utilize the clinical ... of,science-based, result-oriented products., Vitivia(TM),s first product ... have long been recognized as important tools ...
... 27 Debiopharm Group,(Debiopharm), a global independent ... and particularly oncology, today,announced the establishment of ... Federale de Lausanne (EPFL), focusing on Signal ... million endowment, the objective,of the chair is ...
... combination vaccine against Ebola and Marburg viruses using ... infection in monkeys. Researchers from the U.S. ... report their results today (Feb. 26) at the ... in Baltimore, MD. , VLPs are one of ...
Cached Biology Technology:JSJ Pharmaceuticals Announces Launch of Aesthetic Division - Vitivia(TM) 2Debiopharm and EPFL Establish an Oncology Chair 2Combination vaccine protects monkeys from ebola and Marburg viruses 2
B.D. Hames and D.M. Glover (1996) • This issue covers T-Cell antigen receptor genes; T-Lymphocyte signal transduction; B-Cell activation antibody engineering and the complement system and other ...
...
... Maker, 1. Modular system for large ... up to six lab-cast or precast ... with 18- or 24-cm Immobiline DryStrip ... gel cassettes.Innovative design simplifies loading and ...
ELF® 97 Immunohistochemistry Kit...
Biology Products: